Compare Delta Air Lines, Inc. (DAL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs TG Therapeutics Inc — how do they compare? Delta Air Lines, Inc. trades at $81.1 (market cap $54.02B), while TG Therapeutics Inc trades at $54.84 (market cap $8.16B). The key difference: Delta Air Lines, Inc. is far larger — about 6.6× TG Therapeutics Inc's market cap, and Delta Air Lines, Inc. pays a 1.05% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Delta Air Lines, Inc. for 97 Days and TG Therapeutics Inc for 16 Days on average.
| DAL | TGTX | |
|---|---|---|
Market Cap | $54.02B | $8.16B |
Volume | 9,632,845 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $93.66 | $59.06 |
52-Week Low | $55.65 | $26.94 |
Typical Hold Time | 97 Days | 16 Days |
Enterprise Value | $69.34B | $8.37B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $80.49, down 2.99% on the day, as technical indicators signal bearish momentum with the stock testing support near $80. Fundamentally, the company shows solid profitability with a 5.78% net margin and 20.12% ROE, though Q3 2026 earnings missed expectations. Recent news highlights competitive pressures from United and American's customer poaching efforts and Delta's decision to use Amazon's in-flight internet instead of Starlink.
The investment outlook remains positive with strong analyst support (82% buy ratings) and a $103.36 consensus price target offering 28% upside. Key risks include fuel cost volatility, rising crew expenses, and competitive threats to premium customer retention. Cash flow trends show improvement with net positive flows since 2024.
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
